Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients

Launched by ALEXANDRIA UNIVERSITY · Jan 21, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how obesity affects the blood levels of a medication called cyclosporine in adults with nephrotic syndrome, a condition that causes the body to lose too much protein in the urine. The researchers want to find out if being overweight or obese changes how well this medication works and how safe it is for these patients. They will also explore the best dose of cyclosporine based on a person's weight.

To participate in this study, adults aged 65 to 74 who have been taking cyclosporine along with another medication called prednisolone for at least one month can join. The study is open to both obese and overweight patients (with a body mass index, or BMI, over 25) and normal or underweight individuals who will serve as a comparison group. However, those with severe liver problems, cancer, or who are pregnant or breastfeeding cannot take part. Participants can expect to be monitored closely throughout the trial to ensure their safety and to help researchers gather important information about the effects of cyclosporine in different weight groups.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Obese and overweight Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (BMI\>25 kg/m2)
• • Normal or underweight individuals Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (serving as control group)
• Exclusion Criteria:
• • Hepatic patients liver cirrhosis (moderate to severe liver impairment)
• • Cancer patients,
• • Pregnant and lactating female patients